Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma

Published:2021-04 Issue:4 Volume:21 Page:257-266.e3
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

El Halabi Layal^ORCID,Adam Julien,Gravelle Pauline,Marty Virginie,Danu Alina,Lazarovici Julien,Ribrag Vincent,Bosq Jacques,Camara-Clayette Valérie,Laurent Camille,Ghez David^ORCID

Funder

DUERTECC

EURONCO

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference29 articles.

1. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma;Ansell;N Engl J Med,2015

2. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma;Chen;J Clin Oncol,2017

3. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial;Younes;Lancet Oncol,2016

4. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure;Armand;J Clin Oncol,2016

5. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups;Andrews;Nat Immunol,2019

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas;Frontiers in Oncology;2024-07-18

2. Cross-domain information fusion for enhanced cell population delineation in single-cell spatial-omics data;2024-05-14

3. Emerging immunotherapies in the Hodgkin lymphoma armamentarium;Expert Opinion on Emerging Drugs;2024-05-06

4. Other Immune Checkpoint Targets of Interest;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

5. Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade;Cancer Immunology, Immunotherapy;2024-02-13